Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors
Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 3260-3281
DOI: 10.1021/acs.jmedchem.4c02478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.01.2025. Verfasst von Kai Ran und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts …. Hauptthemen laut MEDLINE: Pyrimidines, Drug Design, Class I Phosphatidylinositol 3-Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Chongqing Municipal Education Commission, Chongqing University of Arts and Sciences, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
The concomitant inhibition of PI3Kδ and bromodomain and extra-terminal (BET) that exerts a synergistic effect on the B-cell receptor signaling pathway provides a new strategy for the treatment of aggressive diffuse large B-cell lymphoma (DLBCL). Herein, a merged pharmacophore strategy was utilized to discover a series of thieno[3,2-d]pyrimidine derivatives as the first-in-class bifunctional PI3Kδ-BET inhibitors. Through optimization, a highly potent compound (10b) was identified to possess excellent and balanced activities against PI3Kδ [inhibitory concentration (IC50) = 112 ± 8 nM] and BRD4-BD1 (IC50 = 19 ± 1 nM) and exhibited strong antiproliferative activities in DLBCL cells. Notably, this compound demonstrated good PI3Kδ selectivity over other kinases with minimal cytotoxicity in normal cells. Moreover, 10b has a good oral pharmacokinetic profile in mice and achieves outstanding antitumor activity in the SU-DHL-6 xenograft model. Taken together, these results indicate that targeting PI3Kδ and BET with a bifunctional inhibitor is a promising strategy to treat DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, China.
- Department of Pharmacology, College of Medicine, University of Texas Health San Antonio, San Antonio, Texas 78229, United States.
ORCID-Profile: Yong Li, Dian-Yong Tang, Hong-Yu Li, Zhong-Zhu Chen
Förderung
- Chongqing Municipal Education Commission
- Chongqing University of Arts and Sciences
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Ran, K., Huang, J. H., Li, Y., Zhang, Y., Hu, H., Wang, Z., Tang, D. Y., Li, H. Y., Xu, Z. G., & Chen, Z. Z. (2025). Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors. Journal of Medicinal Chemistry, 68(3), 3260-3281. https://doi.org/10.1021/acs.jmedchem.4c02478
Vancouver
Ran K, Huang JH, Li Y, Zhang Y, Hu H, Wang Z, et al. Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors. Journal of Medicinal Chemistry. 2025;68(3):3260-3281. doi:10.1021/acs.jmedchem.4c02478
BibTeX
@article{Ran2025,
author = {Ran, Kai and Huang, Jiu-Hong and Li, Yong and Zhang, Yimei and Hu, Hao and Wang, Zhengyu and Tang, Dian-Yong and Li, Hong-Yu and Xu, Zhi-Gang and Chen, Zhong-Zhu},
title = {Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {3},
pages = {3260--3281},
doi = {10.1021/acs.jmedchem.4c02478}
}
EUVIMED